Filing Details

Accession Number:
0000899243-20-017498
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-23 17:41:00
Reporting Period:
2020-06-19
Accepted Time:
2020-06-23 17:41:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1281933 K Douglas Bratton 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1723783 Bratton Capital Inc. 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1723787 Bratton Capital Management, L.p. 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
1723842 Neuro Line Partners Lp 201 Main Street, Suite 1900
Fort Worth TX 76102
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-06-19 82,481 $24.20 870,554 No 4 S Indirect By Neuro Line Partners, L.P.
Common Stock Disposition 2020-06-19 62,439 $25.00 808,115 No 4 S Indirect By Neuro Line Partners, L.P.
Common Stock Disposition 2020-06-22 65,373 $24.66 742,742 No 4 S Indirect By Neuro Line Partners, L.P.
Common Stock Disposition 2020-06-22 24,683 $25.12 718,059 No 4 S Indirect By Neuro Line Partners, L.P.
Common Stock Disposition 2020-06-23 16,777 $25.69 701,282 No 4 S Indirect By Neuro Line Partners, L.P.
Common Stock Disposition 2020-06-23 3,247 $26.19 698,035 No 4 S Indirect By Neuro Line Partners, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Neuro Line Partners, L.P.
No 4 S Indirect By Neuro Line Partners, L.P.
No 4 S Indirect By Neuro Line Partners, L.P.
No 4 S Indirect By Neuro Line Partners, L.P.
No 4 S Indirect By Neuro Line Partners, L.P.
No 4 S Indirect By Neuro Line Partners, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,644,881 Indirect By AKDL, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.60, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7) and (8).
  2. These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.
  3. (Continued from Footnote 2) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.61 to $25.60, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.94 to $24.93, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.94 to $25.34, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.09 to $26.085, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.105 to $26.32, inclusive.
  9. These shares of common stock of the Issuer are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.
  10. (Continued from Footnote 7) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.